Nuclear receptors in neurodegenerative diseases

A-Gonzalez, 2009, Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR, Immunity, 31, 245, 10.1016/j.immuni.2009.06.018

Akram, 2010, Increased expression of RXRα in dementia: an early harbinger for the cholesterol dyshomeostasis?, Mol. Neurodegener., 5, 36, 10.1186/1750-1326-5-36

Alaynick, 2008, Nuclear receptors, mitochondria and lipid metabolism, Mitochondrion, 8, 329, 10.1016/j.mito.2008.02.001

Altarejos, 2011, CREB and the CRTC co-activators: sensors for hormonal and metabolic signals, Nat. Rev. Mol. Cell Biol., 12, 141, 10.1038/nrm3072

Andersson, 2005, Inactivation of liver X receptor beta leads to adult-onset motor neuron degeneration in male mice, Proc. Natl. Acad. Sci. U. S. A., 102, 3857, 10.1073/pnas.0500634102

Arsenijevic, 2006, Increased infarct size and lack of hyperphagic response after focal cerebral ischemia in peroxisome proliferator-activated receptor beta-deficient mice, J. Cereb. Blood Flow Metab., 26, 433, 10.1038/sj.jcbfm.9600200

Barbiero, 2014, PPAR-α agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson's disease, Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 53C, 35, 10.1016/j.pnpbp.2014.02.009

Barneda-Zahonero, 2012, Nurr1 protein is required for N-methyl-D-aspartic acid (NMDA) receptor-mediated neuronal survival, J. Biol. Chem., 287, 11351, 10.1074/jbc.M111.272427

Barroso, 2013, Tau hyperphosphorylation and increased BACE1 and RAGE levels in the cortex of PPARβ/δ-null mice, Biochim. Biophys. Acta, 1832, 1241, 10.1016/j.bbadis.2013.03.006

Beaven, 2006, Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia, Annu. Rev. Med., 57, 313, 10.1146/annurev.med.57.121304.131428

Boehm-Cagan, 2014, Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene, J. Neurosci., 34, 7293, 10.1523/JNEUROSCI.5198-13.2014

Braissant, 1996, Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat, Endocrinology, 137, 354, 10.1210/endo.137.1.8536636

Breidert, 2002, Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease, J. Neurochem., 82, 615, 10.1046/j.1471-4159.2002.00990.x

Bridi, 2013, The NR4A orphan nuclear receptors mediate transcription-dependent hippocampal synaptic plasticity, Neurobiol. Learn. Mem., 105, 151, 10.1016/j.nlm.2013.06.020

Brown, 2004, Differential expression of cholesterol hydroxylases in Alzheimer's disease, J. Biol. Chem., 279, 34674, 10.1074/jbc.M402324200

Carta, 2013, Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease?, Neurotox. Res., 23, 112, 10.1007/s12640-012-9342-7

Carta, 2011, Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model, Neuroscience, 194, 250, 10.1016/j.neuroscience.2011.07.046

Castrillo, 2004, Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation, Annu. Rev. Cell Dev. Biol., 20, 455, 10.1146/annurev.cellbio.20.012103.134432

Chawla, 2001, Nuclear receptors and lipid physiology: opening the X-files, Science (New York, N.Y.), 294, 1866, 10.1126/science.294.5548.1866

Chen, 2014, Bexarotene nanocrystal—oral and parenteral formulation development, characterization and pharmacokinetic evaluation, Eur. J. Pharm. Biopharm., 87, 160, 10.1016/j.ejpb.2013.12.005

Chiang, 2010, Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma, Hum. Mol. Genet., 19, 4043, 10.1093/hmg/ddq322

Close, 2013, NR4A orphan nuclear receptors in glucose homeostasis: a minireview, Diabetes Metab., 39, 478, 10.1016/j.diabet.2013.07.005

Colton, 2009, Heterogeneity of microglial activation in the innate immune response in the brain, J. Neuroimmune Pharmacol., 4, 399, 10.1007/s11481-009-9164-4

Combs, 2000, Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists, J. Neurosci., 20, 558, 10.1523/JNEUROSCI.20-02-00558.2000

Craft, 2013, Insulin and Alzheimer's disease: untangling the web, J. Alzheimers Dis., 33, S263

Cramer, 2012, ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models, Science (New York, N.Y.), 335, 1503, 10.1126/science.1217697

Cui, 2012, Liver X receptor activation attenuates inflammatory response and protects cholinergic neurons in APP/PS1 transgenic mice, Neuroscience, 210, 200, 10.1016/j.neuroscience.2012.02.047

Czirr, 2012, The immunology of neurodegeneration, J. Clin. Invest., 122, 1156, 10.1172/JCI58656

Dai, 2012, Liver X receptor β protects dopaminergic neurons in a mouse model of Parkinson disease, Proc. Natl. Acad. Sci. U. S. A., 109, 13112, 10.1073/pnas.1210833109

Dawson, 2012, The retinoid X receptors and their ligands, Biochim. Biophys. Acta, 1821, 21, 10.1016/j.bbalip.2011.09.014

de Ortiz, 1996, HZF-3, an immediate-early orphan receptor homologous to NURR1/NOT: induction upon membrane depolarization and seizures, Mol. Brain Res., 38, 1, 10.1016/0169-328X(95)00263-R

de Urquiza, 2000, Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain, Science (New York, N.Y.), 290, 2140, 10.1126/science.290.5499.2140

Debernard, 2012, Differences in NGFI-B, Nurr1, and NOR-1 expression and nucleocytoplasmic translocation in glutamate-treated neurons, Neurochem. Int., 61, 79, 10.1016/j.neuint.2012.04.002

Decressac, 2012, α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons, Sci. Transl. Med., 4, 163ra156, 10.1126/scitranslmed.3004676

Decressac, 2013, NURR1 in Parkinson disease-from pathogenesis to therapeutic potential, Nat. Rev. Neurol., 9, 629, 10.1038/nrneurol.2013.209

Dehmer, 2004, Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation, J. Neurochem., 88, 494, 10.1046/j.1471-4159.2003.02210.x

Denner, 2012, Cognitive enhancement with rosiglitazone links the hippocampal PPARγ and ERK MAPK signaling pathways, J. Neurosci., 32, 16725, 10.1523/JNEUROSCI.2153-12.2012

Dickey, 2003, Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein+presenilin-1 transgenic mice, J. Neurosci., 23, 5219, 10.1523/JNEUROSCI.23-12-05219.2003

Donkin, 2010, ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice, J. Biol. Chem., 285, 34144, 10.1074/jbc.M110.108100

Dumont, 2012, Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice, Hum. Mol. Genet., 21, 5091, 10.1093/hmg/dds355

Dupuis, 2012, A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis, PLoS ONE, 7, e37885, 10.1371/journal.pone.0037885

Escribano, 2009, Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model, Biochem. Biophys. Res. Commun., 379, 406, 10.1016/j.bbrc.2008.12.071

Escribano, 2010, Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology, Neuropsychopharmacology, 35, 1593, 10.1038/npp.2010.32

España, 2010, beta-Amyloid disrupts activity-dependent gene transcription required for memory through the CREB coactivator CRTC1, J. Neurosci., 30, 9402, 10.1523/JNEUROSCI.2154-10.2010

Ferreira, 2014, Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease, Alzheimers Dement., 10, S76, 10.1016/j.jalz.2013.12.010

Fitz, 2010, Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice, J. Neurosci., 30, 6862, 10.1523/JNEUROSCI.1051-10.2010

Fitz, 2013, Comment on “ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models”, Science (New York, N.Y.), 340, 924-c, 10.1126/science.1235809

Fitz, 2014, Improvement of memory deficits and amyloid-β clearance in aged APP23 mice treated with a combination of anti-amyloid-β antibody and LXR agonist, J. Alzheimers Dis., 10.3233/JAD-132789

García-Yagüe, 2013, Nuclear import and export signals control the subcellular localization of Nurr1 protein in response to oxidative stress, J. Biol. Chem., 288, 5506, 10.1074/jbc.M112.439190

Ghisletti, 2009, Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways, Genes Dev., 23, 681, 10.1101/gad.1773109

Glass, 2010, Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells, Nat. Rev. Immunol., 10, 365, 10.1038/nri2748

Gold, 2010, Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study, Dement. Geriatr. Cogn. Disord., 30, 131, 10.1159/000318845

Gordon, 2010, Alternative activation of macrophages: mechanism and functions, Immunity, 32, 593, 10.1016/j.immuni.2010.05.007

Hawk, 2012, NR4A nuclear receptors support memory enhancement by histone deacetylase inhibitors, J. Clin. Invest., 122, 3593, 10.1172/JCI64145

Heneka, 2005, Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice, Brain, 128, 1442, 10.1093/brain/awh452

Heneka, 2007, Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders, Nat. Clin. Pract. Neurol., 3, 496, 10.1038/ncpneuro0586

Holla, 2011, Nuclear orphan receptor NR4A2 modulates fatty acid oxidation pathways in colorectal cancer, J. Biol. Chem., 286, 30003, 10.1074/jbc.M110.184697

Hondares, 2006, Endocrinology, 147, 2829, 10.1210/en.2006-0070

Hong, 2008, Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors, Curr. Opin. Genet. Dev., 18, 461, 10.1016/j.gde.2008.07.016

Hu, 2013, Synthesis and identification of new flavonoids targeting liver X receptor β involved pathway as potential facilitators of Aβ clearance with reduced lipid accumulation, J. Med. Chem., 56, 6033, 10.1021/jm301913k

IJpenberg, 2004, In vivo activation of PPAR target genes by RXR homodimers, EMBO J., 23, 2083, 10.1038/sj.emboj.7600209

Im, 2012, Omega-3 fatty acids in anti-inflammation (pro-resolution) and GPCRs, Prog. Lipid Res., 51, 232, 10.1016/j.plipres.2012.02.003

Inestrosa, 2013, Peroxisome proliferators reduce spatial memory impairment, synaptic failure, and neurodegeneration in brains of a double transgenic mice model of Alzheimer's disease, J. Alzheimers Dis., 33, 941, 10.3233/JAD-2012-120397

Ishizawa, 2012, NR4A nuclear receptors mediate carnitine palmitoyltransferase 1A gene expression by the rexinoid HX600, Biochem. Biophys. Res. Commun., 418, 780, 10.1016/j.bbrc.2012.01.102

Iwashita, 2007, Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo, J. Pharmacol. Exp. Ther., 320, 1087, 10.1124/jpet.106.115758

Jagirdar, 2013, The NR4A2 nuclear receptor is recruited to novel nuclear foci in response to UV irradiation and participates in nucleotide excision repair, PLoS ONE, 8, e78075, 10.1371/journal.pone.0078075

Jiang, 2005, Age-dependent dopaminergic dysfunction in Nurr1 knockout mice, Exp. Neurol., 191, 154, 10.1016/j.expneurol.2004.08.035

Jiang, 2008, The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications, CNS Drugs, 22, 1, 10.2165/00023210-200822010-00001

Jiang, 2008, ApoE promotes the proteolytic degradation of Aβ, Neuron, 58, 681, 10.1016/j.neuron.2008.04.010

Jin, 2012, Activation of peroxisome proliferator-activated receptor-δ attenuates glutamate-induced neurotoxicity in HT22 mouse hippocampal cells, J. Neurosci. Res., 90, 1646, 10.1002/jnr.23053

Jin, 2013, Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease, J. Neurochem., 125, 410, 10.1111/jnc.12190

Johri, 2012, Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease, Hum. Mol. Genet., 21, 1124, 10.1093/hmg/ddr541

Johri, 2013, PGC-1α, mitochondrial dysfunction, and Huntington's disease, Free Radic. Biol. Med., 62, 37, 10.1016/j.freeradbiomed.2013.04.016

Kalinin, 2009, A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer's disease, Curr. Alzheimer Res., 6, 431, 10.2174/156720509789207949

Katsouri, 2012, Peroxisome proliferator-activated receptor-γ cofactors in neurodegeneration, IUBMB Life, 64, 958, 10.1002/iub.1097

Kiaei, 2008, Peroxisome proliferator-activated receptor-gamma in amyotrophic lateral sclerosis and Huntington's disease, PPAR Res., 2008, 418765, 10.1155/2008/418765

Kiaei, 2005, Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis, Exp. Neurol., 191, 331, 10.1016/j.expneurol.2004.10.007

Kim, 2008, Liver X receptor beta (LXRbeta): a link between beta-sitosterol and amyotrophic lateral sclerosis–Parkinson's dementia, Proc. Natl. Acad. Sci. U. S. A., 105, 2094, 10.1073/pnas.0711599105

Kim, 2009, The role of apolipoprotein E in Alzheimer's disease, Neuron, 63, 278, 10.1016/j.neuron.2009.06.026

Kliewer, 1997, Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma, Proc. Natl. Acad. Sci. U. S. A., 94, 4318, 10.1073/pnas.94.9.4318

Koldamova, 2005, The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease, J. Biol. Chem., 280, 4079, 10.1074/jbc.M411420200

Kumar, 2009, Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease, Behav. Brain Res., 197, 398, 10.1016/j.bbr.2008.10.010

de la Monte, 2006, Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease, J. Alzheimers Dis., 10, 89, 10.3233/JAD-2006-10113

LaClair, 2013, Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice, Mol. Neurodegener., 8, 18, 10.1186/1750-1326-8-18

Lacombe, 2004, Effect of anti-inflammatory agents on transforming growth factor beta over-expressing mouse brains: a model revised, J. Neuroinflammation, 1, 11, 10.1186/1742-2094-1-11

Laloux, 2012, Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease, Pharmacol. Res., 65, 514, 10.1016/j.phrs.2012.02.008

Landreth, 2008, PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease, Neurotherapeutics, 5, 481, 10.1016/j.nurt.2008.05.003

Landreth, 2013, Response to comments on “ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models”, Science (New York, N.Y.), 340, 924-g, 10.1126/science.1234114

Lee, 2009, Differential SUMOylation of LXRalpha and LXRbeta mediates transrepression of STAT1 inflammatory signaling in IFN-gamma-stimulated brain astrocytes, Mol. Cell, 35, 806, 10.1016/j.molcel.2009.07.021

Lee, 2012, Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats, Toxicol. Lett., 213, 332, 10.1016/j.toxlet.2012.07.016

Lefterov, 2007, Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatment, Mol. Neurodegener., 2, 20, 10.1186/1750-1326-2-20

Madrigal, 2007, Neuroprotective actions of noradrenaline: effects on glutathione synthesis and activation of peroxisome proliferator activated receptor delta, J. Neurochem., 103, 2092, 10.1111/j.1471-4159.2007.04888.x

Malewicz, 2011, Essential role for DNA-PK-mediated phosphorylation of NR4A nuclear orphan receptors in DNA double-strand break repair, Genes Dev., 25, 2031, 10.1101/gad.16872411

Mandrekar-Colucci, 2011, Nuclear receptors as therapeutic targets for Alzheimer's disease, Expert Opin. Ther. Targets, 15, 1085, 10.1517/14728222.2011.594043

Mandrekar-Colucci, 2012, Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease, J. Neurosci., 32, 10117, 10.1523/JNEUROSCI.5268-11.2012

Martin, 2012, Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson's disease, Exp. Neurol., 235, 528, 10.1016/j.expneurol.2012.02.017

Martin, 2013, A peroxisome proliferator-activated receptor-δ agonist provides neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease, Neuroscience, 240, 191, 10.1016/j.neuroscience.2013.02.058

Masciopinto, 2012, Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice, Cell Death Dis., 3, e448, 10.1038/cddis.2012.189

Maxwell, 2006, The NR4A subgroup: immediate early response genes with pleiotropic physiological roles, Nucl. Recept. Signal., 4, e002, 10.1621/nrs.04002

McFarland, 2013, Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson's disease, ACS Chem. Neurosci., 4, 1430, 10.1021/cn400100f

Michelhaugh, 2005, Dopamine neurons express multiple isoforms of the nuclear receptor nurr1 with diminished transcriptional activity, J. Neurochem., 95, 1342, 10.1111/j.1471-4159.2005.03458.x

Mohan, 2012, Molecular pathways: the role of NR4A orphan nuclear receptors in cancer, Clin. Cancer Res., 18, 3223, 10.1158/1078-0432.CCR-11-2953

Moreno, 2004, Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS, Neuroscience, 123, 131, 10.1016/j.neuroscience.2003.08.064

Morita, 2005, Selective allosteric ligand activation of the retinoid X receptor heterodimers of NGFI-B and Nurr1, Biochem. Pharmacol., 71, 98, 10.1016/j.bcp.2005.10.017

Morris, 2013, Microglia: a new frontier for synaptic plasticity, learning and memory, and neurodegenerative disease research, Neurobiol. Learn. Mem., 105, 40, 10.1016/j.nlm.2013.07.002

Mosher, 2014, Microglial dysfunction in brain aging and Alzheimer's disease, Biochem. Pharmacol., 88, 594, 10.1016/j.bcp.2014.01.008

Mudò, 2012, Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease, Cell. Mol. Life Sci., 69, 1153, 10.1007/s00018-011-0850-z

Mukundan, 2009, PPAR-delta senses and orchestrates clearance of apoptotic cells to promote tolerance, Nat. Med., 15, 1266, 10.1038/nm.2048

Nayak, 2014, Microglia development and function, Annu. Rev. Immunol., 32, 367, 10.1146/annurev-immunol-032713-120240

Nenov, 2014, Cognitive enhancing treatment with a PPARγ agonist normalizes dentate granule cell presynaptic function in Tg2576 APP mice, J. Neurosci., 34, 1028, 10.1523/JNEUROSCI.3413-13.2014

Nicolakakis, 2010, The nuclear receptor PPARgamma as a therapeutic target for cerebrovascular and brain dysfunction in Alzheimer's disease, Front. Aging Neurosci., 2, 10.3389/fnagi.2010.00021

Nicolakakis, 2008, Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, J. Neurosci., 28, 9287, 10.1523/JNEUROSCI.3348-08.2008

Núñez, 2010, Retinoid X receptor alpha controls innate inflammatory responses through the up-regulation of chemokine expression, Proc. Natl. Acad. Sci. U. S. A., 107, 10626, 10.1073/pnas.0913545107

Odegaard, 2011, Alternative macrophage activation and metabolism, Annu. Rev. Pathol., 6, 275, 10.1146/annurev-pathol-011110-130138

Odegaard, 2013, The immune system as a sensor of the metabolic state, Immunity, 38, 644, 10.1016/j.immuni.2013.04.001

Odegaard, 2007, Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance, Nature, 447, 1116, 10.1038/nature05894

O'Reilly, 2012, Rosiglitazone improves spatial memory and decreases insoluble Aβ(1-42) in APP/PS1 mice, J. Neuroimmune Pharmacol., 7, 140, 10.1007/s11481-011-9282-7

Ouk, 2013, PPARs: a potential target for a disease-modifying strategy in stroke, Curr. Drug Targets, 14, 752, 10.2174/1389450111314070005

Papadopoulos, 2013, Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer's disease with combined amyloid-β and cerebrovascular pathology, PLoS ONE, 8, e68612, 10.1371/journal.pone.0068612

Park, 2011, Scavenger receptor CD36 is essential for the cerebrovascular oxidative stress and neurovascular dysfunction induced by amyloid-beta, Proc. Natl. Acad. Sci. U. S. A., 108, 5063, 10.1073/pnas.1015413108

Parra-Damas, 2014, Crtc1 activates a transcriptional program deregulated at early Alzheimer's disease-related stages, J. Neurosci. Off. J. Soc. Neurosci., 34, 5776, 10.1523/JNEUROSCI.5288-13.2014

Paterniti, 2010, Evidence for the role of peroxisome proliferator-activated receptor-beta/delta in the development of spinal cord injury, J. Pharmacol. Exp. Ther., 333, 465, 10.1124/jpet.110.165605

Pedersen, 2006, Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice, Exp. Neurol., 199, 265, 10.1016/j.expneurol.2006.01.018

Peters, 2000, Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta), Mol. Cell. Biol., 20, 5119, 10.1128/MCB.20.14.5119-5128.2000

Pialat, 2007, MRI monitoring of focal cerebral ischemia in peroxisome proliferator-activated receptor (PPAR)-deficient mice, NMR Biomed., 20, 335, 10.1002/nbm.1157

Polak, 2005, Protective effects of a peroxisome proliferator-activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis, J. Neuroimmunol., 168, 65, 10.1016/j.jneuroim.2005.07.006

Price, 2013, Comment on “ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models”, Science (New York, N.Y.), 340, 924-d, 10.1126/science.1234089

Quinn, 2008, The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B, Br. J. Pharmacol., 154, 226, 10.1038/bjp.2008.78

Riddell, 2007, The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease, Mol. Cell. Neurosci., 34, 621, 10.1016/j.mcn.2007.01.011

Rodriguez-Rivera, 2011, Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status, Behav. Brain Res., 216, 255, 10.1016/j.bbr.2010.08.002

Rőszer, 2013, Retinoid X receptors in macrophage biology, Trends Endocrinol. Metab., 24, 460, 10.1016/j.tem.2013.04.004

Sacchetti, 2006, Multiple signaling pathways regulate the transcriptional activity of the orphan nuclear receptor NURR1, Nucleic Acids Res., 34, 5515, 10.1093/nar/gkl712

Sacchetti, 2009, Liver X receptors and oxysterols promote ventral midbrain neurogenesis in vivo and in human embryonic stem cells, Cell Stem Cell, 5, 409, 10.1016/j.stem.2009.08.019

Sadeghian, 2012, Full and partial peroxisome proliferation-activated receptor-γ agonists, but not δ agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression, J. Neuroimmunol., 246, 69, 10.1016/j.jneuroim.2012.03.010

Saijo, 2009, A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death, Cell, 137, 47, 10.1016/j.cell.2009.01.038

Saijo, 2013, Regulation of microglia activation and deactivation by nuclear receptors, Glia, 61, 104, 10.1002/glia.22423

Sastre, 2006, Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma, Proc. Natl. Acad. Sci. U. S. A., 103, 443, 10.1073/pnas.0503839103

Saucedo-Cardenas, 1996, Comparative distribution of NURR1 and NUR77 nuclear receptors in the mouse central nervous system, J. Mol. Neurosci., 7, 51, 10.1007/BF02736848

Schintu, 2009, PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease, Eur. J. Neurosci., 29, 954, 10.1111/j.1460-9568.2009.06657.x

Schütz, 2005, The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice, J. Neurosci. Off. J. Soc. Neurosci., 25, 7805, 10.1523/JNEUROSCI.2038-05.2005

Searcy, 2012, Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease, J. Alzheimers Dis., 30, 943, 10.3233/JAD-2012-111661

Semple, 2011, Broad-spectrum neuroprotection against traumatic brain injury by agonism of peroxisome proliferator-activated receptors, Exp. Neurol., 229, 195, 10.1016/j.expneurol.2011.02.002

Shibata, 2008, Effects of the PPARgamma activator pioglitazone on p38 MAP kinase and IkappaBalpha in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis, Neuropathology, 28, 387, 10.1111/j.1440-1789.2008.00890.x

Shin, 2011, PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease, Cell, 144, 689, 10.1016/j.cell.2011.02.010

Sirin, 2010, The orphan nuclear receptor Nurr1 restricts the proliferation of haematopoietic stem cells, Nat. Cell Biol., 12, 1213, 10.1038/ncb2125

Smith, 2004, Effect of the peroxisome proliferator-activated receptor beta activator GW0742 in rat cultured cerebellar granule neurons, J. Neurosci. Res., 77, 240, 10.1002/jnr.20153

Sodhi, 2011, Neuroprotective mechanisms of peroxisome proliferator-activated receptor agonists in Alzheimer's disease, Naunyn Schmiedeberg's Arch. Pharmacol., 384, 115, 10.1007/s00210-011-0654-6

Swanson, 2011, The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys, J. Neuroinflammation, 8, 91, 10.1186/1742-2094-8-91

Swanson, 2013, Neuroprotective properties of a novel non-thiazoledinedione partial PPAR- γ agonist against MPTP, PPAR Res., 2013, 582809, 10.1155/2013/582809

Széles, 2010, Research resource: transcriptome profiling of genes regulated by RXR and its permissive and nonpermissive partners in differentiating monocyte-derived dendritic cells, Mol. Endocrinol., 24, 2218, 10.1210/me.2010-0215

Terwel, 2011, Critical role of astroglial apolipoprotein E and liver X receptor-α expression for microglial Aβ phagocytosis, J. Neurosci., 31, 7049, 10.1523/JNEUROSCI.6546-10.2011

Tesseur, 2013, Comment on “ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models”, Science (New York, N.Y.), 340, 924-e, 10.1126/science.1233937

Theofilopoulos, 2012, Brain endogenous liver X receptor ligands selectively promote midbrain neurogenesis, Nat. Chem. Biol., 9, 126, 10.1038/nchembio.1156

Toledo, 2009, Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1ΔE9 mouse model of Alzheimer's disease, Mol. Psychiatry, 15, 272, 10.1038/mp.2009.72

Ulrich, 2013, In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis, Mol. Neurodegener., 8, 13, 10.1186/1750-1326-8-13

Ulusoy, 2011, Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease, Brain Res. Bull., 85, 380, 10.1016/j.brainresbull.2011.05.001

Uppalapati, 2014, Neuroprotective potential of peroxisome proliferator activated receptor-α agonist in cognitive impairment in Parkinson's disease: behavioral, biochemical, and PBPK profile, PPAR Res., 2014, 753587, 10.1155/2014/753587

Vanmierlo, 2011, Liver X receptor activation restores memory in aged AD mice without reducing amyloid, Neurobiol. Aging, 32, 1262, 10.1016/j.neurobiolaging.2009.07.005

Veeraraghavalu, 2013, Comment on “ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models”, Science (New York, N.Y.), 340, 924-f, 10.1126/science.1235505

Volakakis, 2009, NR4A orphan nuclear receptors influence retinoic acid and docosahexaenoic acid signaling via up-regulation of fatty acid binding protein 5, Biochem. Biophys. Res. Commun., 390, 1186, 10.1016/j.bbrc.2009.10.116

Volakakis, 2010, NR4A orphan nuclear receptors as mediators of CREB-dependent neuroprotection, Proc. Natl. Acad. Sci. U. S. A., 107, 12317, 10.1073/pnas.1007088107

Wang, 2002, Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration, Proc. Natl. Acad. Sci. U. S. A., 99, 13878, 10.1073/pnas.172510899

Wesson, 2011, Sensory network dysfunction, behavioral impairments, and their reversibility in an Alzheimer's β-amyloidosis mouse model, J. Neurosci. Off. J. Soc. Neurosci., 31, 15962, 10.1523/JNEUROSCI.2085-11.2011

Whitney, 2002, Regulation of cholesterol homeostasis by the liver X receptors in the central nervous system, Mol. Endocrinol., 16, 1378, 10.1210/mend.16.6.0835

Xiao, 2010, Genetic ablation of steroid receptor coactivator-3 promotes PPAR-beta-mediated alternative activation of microglia in experimental autoimmune encephalomyelitis, Glia, 58, 932, 10.1002/glia.20975

Yamanaka, 2012, PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice, J. Neurosci., 32, 17321, 10.1523/JNEUROSCI.1569-12.2012

Yan, 2003, Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease, J. Neurosci., 23, 7504, 10.1523/JNEUROSCI.23-20-07504.2003

Yang, 2012, miR-132 regulates the differentiation of dopamine neurons by directly targeting Nurr1 expression, J. Cell Sci., 125, 1673, 10.1242/jcs.086421

Yin, 2010, Peroxisome proliferator-activated receptor delta regulation of miR-15a in ischemia-induced cerebral vascular endothelial injury, J. Neurosci., 30, 6398, 10.1523/JNEUROSCI.0780-10.2010

Yin, 2011, Vascular PPARδ protects against stroke-induced brain injury, Arterioscler. Thromb. Vasc. Biol., 31, 574, 10.1161/ATVBAHA.110.221267

Zelcer, 2006, Liver X receptors as integrators of metabolic and inflammatory signaling, J. Clin. Invest., 116, 607, 10.1172/JCI27883

Zelcer, 2007, Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors, Proc. Natl. Acad. Sci. U. S. A., 104, 10601, 10.1073/pnas.0701096104

Zetterström, 1996, Cellular expression of the immediate early transcription factors Nurr1 and NGFI-B suggests a gene regulatory role in several brain regions including the nigrostriatal dopamine system, Brain Res. Mol. Brain Res., 41, 111, 10.1016/0169-328X(96)00074-5

Zhang-Gandhi, 2007, Liver X receptor and retinoid X receptor agonists inhibit inflammatory responses of microglia and astrocytes, J. Neuroimmunol., 183, 50, 10.1016/j.jneuroim.2006.11.007

Zlokovic, 2013, Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease, JAMA Neurol., 70, 440, 10.1001/jamaneurol.2013.2152